Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial
Standard
Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. / Siepmann, Dorothee; Lotts, Tobias; Blome, Christine; Braeutigam, Matthias; Phan, Ngoc Quan; Butterfass-Bahloul, Trude; Augustin, Matthias; Luger, Thomas A; Ständer, Sonja.
in: DERMATOLOGY, Jahrgang 227, Nr. 4, 01.01.2013, S. 353-60.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial
AU - Siepmann, Dorothee
AU - Lotts, Tobias
AU - Blome, Christine
AU - Braeutigam, Matthias
AU - Phan, Ngoc Quan
AU - Butterfass-Bahloul, Trude
AU - Augustin, Matthias
AU - Luger, Thomas A
AU - Ständer, Sonja
PY - 2013/1/1
Y1 - 2013/1/1
N2 - BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.
AB - BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.
U2 - 10.1159/000355671
DO - 10.1159/000355671
M3 - SCORING: Journal article
C2 - 24281309
VL - 227
SP - 353
EP - 360
JO - DERMATOLOGY
JF - DERMATOLOGY
SN - 1018-8665
IS - 4
ER -